TrialDiabetes, obesity & metabolism2020

Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study).

Kyu Yong Cho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.